Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mireia Pérez-Verdaguer, Jesusa Capera, Clara Serrano-Novillo, Irene Estadella, Daniel Sastre & Antonio Felipe. (2016) The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies. Expert Opinion on Therapeutic Targets 20:5, pages 577-591.
Read now
Read now
Yina H Huang, Kasper Hoebe & Karsten Sauer. (2008) New therapeutic targets in immune disorders: ItpkB, Orai1 and UNC93B. Expert Opinion on Therapeutic Targets 12:4, pages 391-413.
Read now
Read now
Articles from other publishers (19)
Masoomeh Shirzaiy, Zohreh Dalirsani, Payam Peymankar & Mahboobeh Taherizadeh. (2023)
Relationship between salivary levels of interleukin‐8 and
HbA1c
in patients with type 2 diabetes
. Endocrinology, Diabetes & Metabolism 6:6.
Crossref
Crossref
Mostafa Abohelwa, Jonathan Kopel, Scott Shurmur, Mohammad M. Ansari, Yogesh Awasthi & Sanjay Awasthi. (2023) The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. Journal of Vascular Diseases 2:1, pages 122-164.
Crossref
Crossref
Xian-Tao Li. (2022) Beneficial effects of carvedilol modulating potassium channels on the control of glucose. Biomedicine & Pharmacotherapy 150, pages 113057.
Crossref
Crossref
Tesfahun Dessale Admasu, Diogo Barardo, Li Fang Ng, Krishna Chaithanya Batchu, Amaury Cazenave-Gassiot, Markus R. Wenk & Jan Gruber. (2021) A small-molecule Psora-4 acts as a caloric restriction mimetic to promote longevity in C. elegans. GeroScience 44:2, pages 1029-1046.
Crossref
Crossref
Raymond S. Norton & K. George Chandy. (2017) Venom-derived peptide inhibitors of voltage-gated potassium channels. Neuropharmacology 127, pages 124-138.
Crossref
Crossref
Christopher P. Kovach, Dolly Al Koborssy, Zhenbo Huang, Brandon M. Chelette, James M. Fadool & Debra A. Fadool. (2016) Mitochondrial Ultrastructure and Glucose Signaling Pathways Attributed to the Kv1.3 Ion Channel. Frontiers in Physiology 7.
Crossref
Crossref
Wilson Edwards, Wai-Ping Fung-Leung, Chichi Huang, Ellen Chi, Nancy Wu, Yi Liu, Michael P. Maher, Rachelle Bonesteel, Judith Connor, Ross Fellows, Elena Garcia, Jerry Lee, Lu Lu, Karen Ngo, Brian Scott, Hong Zhou, Ronald V. Swanson & Alan D. Wickenden. (2014) Targeting the Ion Channel Kv1.3 with Scorpion Venom Peptides Engineered for Potency, Selectivity, and Half-life. Journal of Biological Chemistry 289:33, pages 22704-22714.
Crossref
Crossref
Kseniya S. Kudryashova, Oksana V. Nekrasova, Alexey I. Kuzmenkov, Alexander A. Vassilevski, Anastasia A. Ignatova, Yuliya V. Korolkova, Eugene V. Grishin, Mikhail P. Kirpichnikov & Alexey V. Feofanov. (2013) Fluorescent system based on bacterial expression of hybrid KcsA channels designed for Kv1.3 ligand screening and study. Analytical and Bioanalytical Chemistry 405:7, pages 2379-2389.
Crossref
Crossref
Yong Yang, Yan-Fu Wang, Xiao-Fang Yang, Zhao-Hui Wang, Yi-Tian Lian, Ying Yang, Xiao-Wei Li, Xiang Gao, Jian Chen, Yan-Wen Shu, Long-Xian Cheng, Yu-Hua Liao & Kun Liu. (2013) Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL. Journal of Lipid Research 54:1, pages 34-43.
Crossref
Crossref
Rende Xu, Ming Cao, Xiaofen Wu, Xingfen Wang, Lei Ruan, Xiaoqing Quan, Caixia Lü, Wei He & Cuntai Zhang. (2012) Kv1.3 channels as a potential target for immunomodulation of CD4+CD28null T cells in patients with acute coronary syndrome. Clinical Immunology 142:2, pages 209-217.
Crossref
Crossref
Stephen V. Straub, Sylvie M. Perez, Beijing Tan, Kimberly A. Coughlan, Catherine E. Trebino, Patricia Cosgrove, Joanne M. Buxton, John M. Kreeger & V. Margaret Jackson. (2011) Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues. American Journal of Physiology-Endocrinology and Metabolism 301:2, pages E380-E390.
Crossref
Crossref
Curt D. Haffner, Stephen A. Thomson, Yu Guo, Lee T. Schaller, Sharon Boggs, Scott Dickerson, Jeff Gobel, Dan Gillie & J. Patrick Condreay. (2010) N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1. Bioorganic & Medicinal Chemistry Letters 20:23, pages 6983-6988.
Crossref
Crossref
Curt D. Haffner, Stephen A. Thomson, Yu Guo, Kimberly Petrov, Andrew Larkin, Pierette Banker, Gregory Schaaf, Scott Dickerson, Jeff Gobel, Dan Gillie, J. Patrick Condreay, Chuck Poole, Tiffany Carpenter & John Ulrich. (2010) Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorganic & Medicinal Chemistry Letters 20:23, pages 6989-6992.
Crossref
Crossref
Bok Hee Choi & Sang June Hahn. (2010) Kv1.3: a potential pharmacological target for diabetes. Acta Pharmacologica Sinica 31:9, pages 1031-1035.
Crossref
Crossref
Kathryn A. Lindl, David R. Marks, Dennis L. Kolson & Kelly L. Jordan-Sciutto. (2010) HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic Opportunities. Journal of Neuroimmune Pharmacology 5:3, pages 294-309.
Crossref
Crossref
Kun Liu, Manoj Samuel, Jeff Tillett, James K. Hennan, Belew Mekonnen, Veronica Soloveva, Richard K. Harrison, Jeff W. Paslay & James Larocque. (2010) High-Throughput Screening for Kv1.3 Channel Blockers Using an Improved FLIPR-Based Membrane-Potential Assay. SLAS Discovery 15:2, pages 185-195.
Crossref
Crossref
Elizabeth P. Ryan & Henry J. Thompson. 2009. Endogenous Toxins. Endogenous Toxins
881
906
.
Sikander GillRajwant GillDavid WicksDong Liang. (2007)
A Cell-Based Rb
+
-Flux Assay of the Kv1.3 Potassium Channel
. ASSAY and Drug Development Technologies 5:3, pages 373-380.
Crossref
Crossref
J.G. McGivern & J.F. WorleyIIIIII. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
827
875
.